Citations (56)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Huimin Dan, Shanshan Zhang, Yongning Zhou & Quanlin Guan. (2019) DNA Methyltransferase Inhibitors: Catalysts For Antitumour Immune Responses. OncoTargets and Therapy 12, pages 10903-10916.
Read now
Read now
Ashley R. Maiuri, Sudha S. Savant, Ram Podicheti, Douglas B. Rusch & Heather M. O’Hagan. (2019) DNA methyltransferase inhibition reduces inflammation-induced colon tumorigenesis. Epigenetics 14:12, pages 1209-1223.
Read now
Read now
Jan Philipp Bewersdorf, Maximilian Stahl & Amer M. Zeidan. (2019) Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled. Expert Review of Anticancer Therapy 19:5, pages 393-404.
Read now
Read now
Simone Jueliger, John Lyons, Sara Cannito, Illar Pata, Pille Pata, Marianna Shkolnaya, Oriana Lo Re, Marion Peyrou, Francesc Villarroya, Valerio Pazienza, Francesca Rappa, Francesco Cappello, Mohammad Azab, Pietro Taverna & Manlio Vinciguerra. (2016) Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma. Epigenetics 11:10, pages 709-720.
Read now
Read now
Wa Zhang, Carter J Barger, Petra A Link, Paulette Mhawech-Fauceglia, Austin Miller, Stacey N Akers, Kunle Odunsi & Adam R Karpf. (2015) DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer. Epigenetics 10:8, pages 736-748.
Read now
Read now
Articles from other publishers (51)
Manish Malviya, Zita E. H. Aretz, Zaki Molvi, Jayop Lee, Stephanie Pierre, Patrick Wallisch, Tao Dao & David A. Scheinberg. (2023)
Challenges and solutions for therapeutic
TCR
‐based agents
. Immunological Reviews 320:1, pages 58-82.
Crossref
Crossref
Lin Zhao, Xi Chen, Honghai Wu, Qiaojun He, Ling Ding & Bo Yang. (2023) Strategies to synergize PD-1/PD-L1 targeted cancer immunotherapies to enhance antitumor responses in ovarian cancer. Biochemical Pharmacology 215, pages 115724.
Crossref
Crossref
Shi-Yi Lyu, Wang Xiao, Guang-Zu Cui, Cheng Yu, Huan Liu, Min Lyu, Qian-Ya Kuang, En-Hua Xiao & Yong-Heng Luo. (2023) Role and mechanism of DNA methylation and its inhibitors in hepatic fibrosis. Frontiers in Genetics 14.
Crossref
Crossref
Adriana Amaro, Francesco Reggiani, Daniela Fenoglio, Rosaria Gangemi, Anna Tosi, Alessia Parodi, Barbara Banelli, Valentina Rigo, Luca Mastracci, Federica Grillo, Alessandra Cereghetti, Aizhan Tastanova, Adhideb Ghosh, Fabio Sallustio, Laura Emionite, Antonio Daga, Tiziana Altosole, Gilberto Filaci, Antonio Rosato, Mitchell Levesque, Michele Maio, Ulrich Pfeffer & Michela Croce. (2023) Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells. Journal of Experimental & Clinical Cancer Research 42:1.
Crossref
Crossref
Sofie Traynor, Mikkel Green Terp, Aaraby Yoheswaran Nielsen, Per Guldberg, Mie Jakobsen, Pernille Gejl Pedersen, Odd Lilleng Gammelgaard, Christina Bøg Pedersen, Mathilde Thybo Pedersen, Sofie Rattenborg, Henrik Jørn Ditzel & Morten Frier Gjerstorff. (2023) DNA methyltransferase inhibition promotes recruitment of myeloid-derived suppressor cells to the tumor microenvironment through induction of tumor cell-intrinsic interleukin-1. Cancer Letters 552, pages 215982.
Crossref
Crossref
Synat Kang, Lixin Wang, Lu Xu, Ruiqi Wang, Qingzheng Kang, Xuefeng Gao & Li Yu. (2022) Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory phenotype. Oncogene 41:42, pages 4696-4708.
Crossref
Crossref
Shiro Koizume, Tomoko Takahashi, Yoshiyasu Nakamura, Mitsuyo Yoshihara, Yukihide Ota, Shinya Sato, Hiroko Tadokoro, Tomoyuki Yokose, Hisamori Kato, Etsuko Miyagi & Yohei Miyagi. (2022) Lipophagy-ICAM-1 pathway associated with fatty acid and oxygen deficiencies is involved in poor prognoses of ovarian clear cell carcinoma. British Journal of Cancer 127:3, pages 462-473.
Crossref
Crossref
Lin Zhao, Hongjie Guo, Xi Chen, Wenxin Zhang, Qiaojun He, Ling Ding & Bo Yang. (2022) Tackling drug resistance in ovarian cancer with epigenetic targeted drugs. European Journal of Pharmacology 927, pages 175071.
Crossref
Crossref
Ping Yang, Yingnan Qiao, Mei Meng & Quansheng Zhou. (2022) Cancer/Testis Antigens as Biomarker and Target for the Diagnosis, Prognosis, and Therapy of Lung Cancer. Frontiers in Oncology 12.
Crossref
Crossref
Pavlina Spiliopoulou, Sarah Spear, Hasan Mirza, Ian Garner, Lynn McGarry, Fabio Grundland-Freile, Zhao Cheng, Darren P. Ennis, Nayana Iyer, Sophie McNamara, Marina Natoli, Susan Mason, Karen Blyth, Peter D. Adams, Patricia Roxburgh, Matthew J. Fuchter, Bob Brown & Iain A. McNeish. (2022) Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma. Molecular Cancer Therapeutics 21:4, pages 522-534.
Crossref
Crossref
Brandie C. Taylor & Justin M. Balko. (2022) Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response. Frontiers in Immunology 13.
Crossref
Crossref
Daniel J. Weisenberger, Ranjani Lakshminarasimhan & Gangning Liang. 2022. DNA Methyltransferases - Role and Function. DNA Methyltransferases - Role and Function
317
348
.
Weiwei Xie, Huizhen Sun, Xiaoduan Li, Feikai Lin, Ziliang Wang & Xipeng Wang. (2021) Ovarian cancer: epigenetics, drug resistance, and progression. Cancer Cell International 21:1.
Crossref
Crossref
Tatiana Montoya, María Luisa Castejón, Rocío Muñoz-García & Catalina Alarcón-de-la-Lastra. (2021) Epigenetic linkage of systemic lupus erythematosus and nutrition. Nutrition Research Reviews, pages 1-21.
Crossref
Crossref
Jun Wang, Arielle Elkrief, Wei Guo, Neerav Shukla, Mrinal Gounder & Marc Ladanyi. (2021) Prospects for Epigenetic Targeted Therapies of Bone and Soft-Tissue Sarcomas. Sarcoma 2021, pages 1-7.
Crossref
Crossref
Kah Keng Wong. (2021) DNMT1: A key drug target in triple-negative breast cancer. Seminars in Cancer Biology 72, pages 198-213.
Crossref
Crossref
Weini Wang, Fang Fang, Ali Ozes & Kenneth P. Nephew. (2021) Targeting Ovarian Cancer Stem Cells by Dual Inhibition of HOTAIR and DNA Methylation. Molecular Cancer Therapeutics 20:6, pages 1092-1101.
Crossref
Crossref
Rory M. Shallis, Robert P. Gale, Hillard M. Lazarus, Kenneth B. Roberts, Mina L. Xu, Stuart E. Seropian, Steven D. Gore & Nikolai A. Podoltsev. (2021) Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved. Blood Reviews 47, pages 100773.
Crossref
Crossref
Mie K. Jakobsen, Sofie Traynor, Mette Stæhr, Pascal G. Duijf, Aaraby Y. Nielsen, Mikkel G. Terp, Christina B. Pedersen, Per Guldberg, Henrik J. Ditzel & Morten F. Gjerstorff. (2021) The Cancer/Testis Antigen Gene VCX2 Is Rarely Expressed in Malignancies but Can Be Epigenetically Activated Using DNA Methyltransferase and Histone Deacetylase Inhibitors. Frontiers in Oncology 10.
Crossref
Crossref
Jan Philipp Bewersdorf, Rory M. Shallis & Amer M. Zeidan. (2021) Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways. Blood Reviews 45, pages 100709.
Crossref
Crossref
Md Gias Uddin & Tamer E. Fandy. 2021.
205
223
.
Maureen L. Drakes & Patrick J. Stiff. 2021. Ovarian Cancer: Molecular & Diagnostic Imaging and Treatment Strategies. Ovarian Cancer: Molecular & Diagnostic Imaging and Treatment Strategies
33
54
.
Jose RussoJose Russo. 2021. The Future of Prevention and Treatment of Breast Cancer. The Future of Prevention and Treatment of Breast Cancer
75
105
.
Isamu Hoshino, Yoshihiro Nabeya, Nobuhiro Takiguchi, Hisashi Gunji, Fumitaka Ishige, Yosuke Iwatate, Akiko Kuwajima, Fumiaki Shiratori, Rei Okada & Hideaki Shimada. (2020) Inducing multiple antibodies to treat squamous cell esophageal carcinoma. BMC Cancer 20:1.
Crossref
Crossref
Aaraby Y. Nielsen, Maria Ormhøj, Sofie Traynor & Morten F. Gjerstorff. (2020) Augmenting engineered T-cell strategies in solid cancers through epigenetic priming. Cancer Immunology, Immunotherapy 69:11, pages 2169-2178.
Crossref
Crossref
Kelly Olino, Tristen Park & Nita Ahuja. (2020) Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance. Seminars in Cancer Biology 65, pages 114-122.
Crossref
Crossref
Kah Keng Wong. (2020) DNMT1 as a therapeutic target in pancreatic cancer: mechanisms and clinical implications. Cellular Oncology 43:5, pages 779-792.
Crossref
Crossref
Jan Philipp Bewersdorf, Hetty Carraway & Thomas Prebet. (2020) Emerging treatment options for patients with high-risk myelodysplastic syndrome. Therapeutic Advances in Hematology 11, pages 204062072095500.
Crossref
Crossref
Boran Pang, Qin Wang, Shipeng Ning, Junqiang Wu, Xingda Zhang, Yanbo Chen & Shouping Xu. (2019) Landscape of tumor suppressor long noncoding RNAs in breast cancer. Journal of Experimental & Clinical Cancer Research 38:1.
Crossref
Crossref
Marcelo L. Ribeiro, Diana Reyes-Garau, Marc Armengol, Miranda Fernández-Serrano & Gaël Roué. (2019) Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma. Frontiers in Genetics 10.
Crossref
Crossref
Yong-Tao Duan, Chetan B. Sangani, Wei Liu, Kunjal V. Soni & Yongfang Yao. (2019) New Promises to Cure Cancer and Other Genetic Diseases/Disorders: Epi-drugs Through Epigenetics. Current Topics in Medicinal Chemistry 19:12, pages 972-994.
Crossref
Crossref
Tyler R. McCaw, Troy D. Randall & Rebecca C. Arend. (2019) Overcoming immune suppression with epigenetic modification in ovarian cancer. Translational Research 204, pages 31-38.
Crossref
Crossref
Jan Philipp Bewersdorf, Rory Shallis, Maximilian Stahl & Amer M. Zeidan. (2019) Epigenetic therapy combinations in acute myeloid leukemia: what are the options?. Therapeutic Advances in Hematology 10, pages 204062071881669.
Crossref
Crossref
Simone Jueliger, Pietro Taverna, Oriana Lo Re & Manlio Vinciguerra. 2019. Handbook of Immunosenescence. Handbook of Immunosenescence
2709
2737
.
Yanrong Su, Nathan R. Hopfinger, Theresa D. Nguyen, Thomas J. Pogash, Julia Santucci-Pereira & Jose Russo. (2018) Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors. Journal of Experimental & Clinical Cancer Research 37:1.
Crossref
Crossref
Khushboo Agrawal, Viswanath Das, Pankhuri Vyas & Marián Hajdúch. (2018) Nucleosidic DNA demethylating epigenetic drugs – A comprehensive review from discovery to clinic. Pharmacology & Therapeutics 188, pages 45-79.
Crossref
Crossref
Ângela Marques-Magalhães, Inês Graça, Rui Henrique & Carmen Jerónimo. (2018) Targeting DNA Methyltranferases in Urological Tumors. Frontiers in Pharmacology 9.
Crossref
Crossref
Elizabeth A. Griffiths, Pragya Srivastava, Junko Matsuzaki, Zachary Brumberger, Eunice S. Wang, Justin Kocent, Austin Miller, Gregory W. Roloff, Hong Yuen Wong, Benjamin E. Paluch, Linda G. Lutgen-Dunckley, Brandon L. Martens, Kunle Odunsi, Adam R. Karpf, Christopher S. Hourigan & Michael J. Nemeth. (2018) NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome. Clinical Cancer Research 24:5, pages 1019-1029.
Crossref
Crossref
Simone Jueliger, Pietro Taverna, Oriana Lo Re & Manlio Vinciguerra. 2018. Handbook of Immunosenescence. Handbook of Immunosenescence
1
30
.
Zhong‑Tian Bai, Bing Bai, Jun Zhu, Cui‑Xia Di, Xun Li & Wen‑Ce Zhou. (2017) Epigenetic actions of environmental factors and promising drugs for cancer therapy (Review). Oncology Letters.
Crossref
Crossref
Ornella Franzese, Francesco Torino, Maria Pia Fuggetta, Angelo Aquino, Mario Roselli, Enzo Bonmassar, Anna Giuliani & Stefania D’Atri. (2017) Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors. Oncotarget 8:25, pages 41641-41669.
Crossref
Crossref
Cornelia Siebenkäs, Katherine B. Chiappinelli, Angela A. Guzzetta, Anup Sharma, Jana Jeschke, Rajita Vatapalli, Stephen B. Baylin & Nita Ahuja. (2017) Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells. PLOS ONE 12:6, pages e0179501.
Crossref
Crossref
Shiro Koizume & Yohei Miyagi. (2017) Potential Coagulation Factor-Driven Pro-Inflammatory Responses in Ovarian Cancer Tissues Associated with Insufficient O2 and Plasma Supply. International Journal of Molecular Sciences 18:4, pages 809.
Crossref
Crossref
Inês Graça, Eva Pereira-Silva, Rui Henrique, Graham Packham, Simon J. Crabb & Carmen Jerónimo. (2016) Epigenetic modulators as therapeutic targets in prostate cancer. Clinical Epigenetics 8:1.
Crossref
Crossref
Hui Tao, Kai-Hu Shi, Jing-Jing Yang & Jun Li. (2016) Epigenetic mechanisms in atrial fibrillation: New insights and future directions. Trends in Cardiovascular Medicine 26:4, pages 306-318.
Crossref
Crossref
Katherine B. Chiappinelli, Cynthia A. Zahnow, Nita Ahuja & Stephen B. Baylin. (2016) Combining Epigenetic and Immunotherapy to Combat Cancer. Cancer Research 76:7, pages 1683-1689.
Crossref
Crossref
Pragya Srivastava, Benjamin E. Paluch, Junko Matsuzaki, Smitha R. James, Golda Collamat-Lai, Nadja Blagitko-Dorfs, Laurie Ann Ford, Rafeh Naqash, Michael Lübbert, Adam R. Karpf, Michael J. Nemeth & Elizabeth A. Griffiths. (2016) Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy. Oncotarget 7:11, pages 12840-12856.
Crossref
Crossref
A.R. Maiuri & H.M. O’Hagan. 2016. Molecular and Cellular Changes in the Cancer Cell. Molecular and Cellular Changes in the Cancer Cell
69
117
.
Ranjani Lakshminarasimhan & Gangning Liang. 2016. DNA Methyltransferases - Role and Function. DNA Methyltransferases - Role and Function
151
172
.
Yuting Kuang, Anthony El-Khoueiry, Pietro Taverna, Mats Ljungman & Nouri Neamati. (2015) Guadecitabine (SGI-110) priming sensitizes hepatocellular carcinoma cells to oxaliplatin. Molecular Oncology 9:9, pages 1799-1814.
Crossref
Crossref
James N Lowder, Pietro Taverna & Jean-Pierre J Issa. (2015) Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?. Epigenomics 7:7, pages 1083-1088.
Crossref
Crossref